Rossari Biotech (ROSSARI.NS) Earnings Analysis
Rossari Biotech (ROSSARI.NS) next reports earnings on 2026-10-19. Last quarter (2026-07-18) it missed with EPS 6.4 INR vs 8.8 INR est (-27.3%). It has beaten estimates in 4/8 recent quarters (50%). Trailing P/E 18.05.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ROSSARI.NS next report earnings?
| Next earnings date | 2026-10-19 |
|---|---|
| Consensus EPS estimate | n/a |
| Revenue estimate | n/a |
ROSSARI.NS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-07-18 | 6.4 INR | 8.8 INR | -27.3% | Miss |
| 2026-04-27 | 8.3 INR | 6.3 INR | +31.7% | Beat |
| 2026-01-17 | 5.9 INR | 6.2 INR | -4.8% | Miss |
| 2025-10-15 | 6.7 INR | 6.4 INR | +4.7% | Beat |
| 2025-07-19 | 6.05 INR | 5.4 INR | +12% | Beat |
| 2025-04-25 | 6.2 INR | 5.7 INR | +8.8% | Beat |
| 2025-01-21 | 5.7 INR | 6.1 INR | -6.6% | Miss |
| 2024-10-19 | 6.38 INR | 7.3 INR | -12.6% | Miss |
Beat rate: 4/8 (50%) over reported quarters with consensus data.
ROSSARI.NS valuation and analyst view
| Trailing P/E | 18.05 |
|---|---|
| Trailing EPS | 27.227 INR |
| Price / book | 2.04 |
| Dividend yield | 0.10% |
| Market cap | 27.51B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Rossari Biotech (ROSSARI.NS)'s next earnings date?
Rossari Biotech is next scheduled to report on 2026-10-19.
Did ROSSARI.NS beat earnings last quarter?
In its 2026-07-18 report, ROSSARI.NS posted EPS of 6.4 INR versus a 8.8 INR estimate — a miss of 27.3%.
What is ROSSARI.NS's earnings track record?
Over the last 8 reported quarters with consensus data, ROSSARI.NS beat estimates 4 times (50%).
What is ROSSARI.NS's current P/E ratio and EPS?
ROSSARI.NS trades at a trailing P/E of 18.05 on trailing EPS of 27.226501579173945 INR.
What do analysts rate ROSSARI.NS?
ROSSARI.NS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.